Author

Arvinda Padmanabhan

Institution: Central Baptist Hospital

Observed institution: Central Baptist Hospital

OpenAlex ID: A5091065198

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

2022 · Meletios A Dimopoulos, Paul G Richardson, et al. · The Lancet Haematology · 47

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer

2019 · Daniel Morgensztern, Michal Rose, et al. · British Journal of Cancer · 40

Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples

2021 · Scott A. Tomlins, Daniel H. Hovelson, et al. · JCO Precision Oncology · 35

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence

2021 · Craig L Slingluff, Karl D Lewis, et al. · Journal for ImmunoTherapy of Cancer · 19

CAMPERR: A multicenter, prospective, observational study to evaluate a cfDNA-based genome-wide methylation enrichment assay for multicancer early detection (MCED), identification of molecular residual disease, and relapse prognostication.

2026 · Gregory Idos, Faith L. Holmes, et al. · Journal of Clinical Oncology

Multicenter phase II trial of RRx-001 in previously treated SCLC.

2019 · Daniel Morgensztern, Michal G. Rose, et al. · Journal of Clinical Oncology

Works count: 6

Citation count: 141

H-index: 4

I10-index: 4